Home › Cachexia › NCT07112196
Visugromab in Cachexia International Trial
Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo in Patients With Cancer-associated Cachexia
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Weight loss * Advanced cancer Exclusion Criteria: * Participation in another interventional clinical trial, receipt of any investigational therapy or use of any investigational device within 4 weeks prior to screening and between screening and the first dose of investigational product
About the study
A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are:
* Does visugromab help participants put weight back on and have a better appetite? * Does visugromab help participants move more and better? * What medical problems do participants have when taking visugromab? Researchers will compare visugromab to a placebo (a look-alike substance that contains no drug).
Participants will visit the hospital or clinic once every 4 weeks to receive visugromab or placebo via a drip into a vein and to undergo checkups and tests.
What is being tested
- Visugromab (CTL-002) (drug)
- Placebo (drug)
- Visugromab (CTL-002) (drug)
- Visugromab (CTL-002) (drug)
Sponsor: CatalYm GmbH · Participants: 518 · Started: Apr 16, 2026
Contact the study team
- Trial Director · Phone: 49 8920006640
Official record on ClinicalTrials.gov — NCT07112196
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.